Table 2. SH3 domain clones selected by intracellular tails of different ADAMs.
| ADAM8 | ADAM9 | ADAM12 | ADAM15 | ADAM19 | |
|---|---|---|---|---|---|
| Dominant | SNX33 | SNX33 | Src* | SNX33* | Tks5(I) |
| TOCA1 | SNX9* | Nephrocystin | |||
| Strongly selected | CIP4 | Tec | Lyn* | Tks5(V)* | Src |
| SNX9 | SNX18 | Tks5(V)* | Src* | RIMBP1(III) | |
| Tec | Hck* | SNX9* | Eps8L1 | ||
| Src | AHI1 | Nephrocystin* | NCF1(I) | ||
| Hck* | |||||
| Tec | |||||
| Lyn* | |||||
| Tks5(I)* | |||||
| Significantly enriched | NCF1(I) | NCF1(I) | SNX33 | p85α* | Tec |
| OSTF1 | Lyn | SNX9 | Btk | Lyn | |
| ArgBP2(II) | NCF1(I)* | p85α | |||
| OSTF1 | Nephrocystin | ||||
| intersectin1(III) | SNX33 | ||||
| TOCA1 | |||||
| SNX9* | |||||
| Tks5(V)* | |||||
| Hck |
SH3 domains repeatedly enriched by affinity screening from the complete and subsequently constructed ADAM-specific reduction libraries. SH3 interactions reported previously are indicated with an asterisk.